235 related articles for article (PubMed ID: 22512582)
1. Novel serine protease dipeptidyl peptidase IV inhibitor: alogliptin.
Agrawal R; Bahare RS; Jain P; Dikshit SN; Ganguly S
Mini Rev Med Chem; 2012 Nov; 12(13):1345-58. PubMed ID: 22512582
[TBL] [Abstract][Full Text] [Related]
2. An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus.
Chen XW; He ZX; Zhou ZW; Yang T; Zhang X; Yang YX; Duan W; Zhou SF
Clin Exp Pharmacol Physiol; 2015 Dec; 42(12):1225-38. PubMed ID: 26218204
[TBL] [Abstract][Full Text] [Related]
3. Alogliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus.
Jarvis CI; Cabrera A; Charron D
Ann Pharmacother; 2013 Nov; 47(11):1532-9. PubMed ID: 24285765
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys.
Lee B; Shi L; Kassel DB; Asakawa T; Takeuchi K; Christopher RJ
Eur J Pharmacol; 2008 Jul; 589(1-3):306-14. PubMed ID: 18538760
[TBL] [Abstract][Full Text] [Related]
5. Alogliptin: A new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus.
Ndefo UA; Okoli O; Erowele G
Am J Health Syst Pharm; 2014 Jan; 71(2):103-9. PubMed ID: 24375601
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects.
Christopher R; Covington P; Davenport M; Fleck P; Mekki QA; Wann ER; Karim A
Clin Ther; 2008 Mar; 30(3):513-27. PubMed ID: 18405789
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes.
Covington P; Christopher R; Davenport M; Fleck P; Mekki QA; Wann ER; Karim A
Clin Ther; 2008 Mar; 30(3):499-512. PubMed ID: 18405788
[TBL] [Abstract][Full Text] [Related]
8. Alogliptin for the treatment of type 2 diabetes.
White JR
Drugs Today (Barc); 2011 Feb; 47(2):99-107. PubMed ID: 21431099
[TBL] [Abstract][Full Text] [Related]
9. Discovery of highly potent DPP-4 inhibitors by hybrid compound design based on linagliptin and alogliptin.
Lai ZW; Li C; Liu J; Kong L; Wen X; Sun H
Eur J Med Chem; 2014 Aug; 83():547-60. PubMed ID: 24996141
[TBL] [Abstract][Full Text] [Related]
10. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.
Feng J; Zhang Z; Wallace MB; Stafford JA; Kaldor SW; Kassel DB; Navre M; Shi L; Skene RJ; Asakawa T; Takeuchi K; Xu R; Webb DR; Gwaltney SL
J Med Chem; 2007 May; 50(10):2297-300. PubMed ID: 17441705
[TBL] [Abstract][Full Text] [Related]
11. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin.
Capuano A; Sportiello L; Maiorino MI; Rossi F; Giugliano D; Esposito K
Drug Des Devel Ther; 2013; 7():989-1001. PubMed ID: 24068868
[TBL] [Abstract][Full Text] [Related]
12. Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism.
Grimshaw CE; Jennings A; Kamran R; Ueno H; Nishigaki N; Kosaka T; Tani A; Sano H; Kinugawa Y; Koumura E; Shi L; Takeuchi K
PLoS One; 2016; 11(6):e0157509. PubMed ID: 27328054
[TBL] [Abstract][Full Text] [Related]
13. Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.
Deacon CF
Curr Opin Investig Drugs; 2008 Apr; 9(4):402-13. PubMed ID: 18393107
[TBL] [Abstract][Full Text] [Related]
14. Highly potent dipeptidyl peptidase IV inhibitors derived from Alogliptin through pharmacophore hybridization and lead optimization.
Xie H; Zeng L; Zeng S; Lu X; Zhao X; Zhang G; Tu Z; Xu H; Yang L; Zhang X; Wang S; Hu W
Eur J Med Chem; 2013 Oct; 68():312-20. PubMed ID: 23994324
[TBL] [Abstract][Full Text] [Related]
15. The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis.
Fujii Y; Abe M; Higuchi T; Mizuno M; Suzuki H; Matsumoto S; Ito M; Maruyama N; Okada K; Soma M
Expert Opin Pharmacother; 2013 Feb; 14(3):259-67. PubMed ID: 23289982
[TBL] [Abstract][Full Text] [Related]
16. Alogliptin benzoate for management of type 2 diabetes.
Saisho Y
Vasc Health Risk Manag; 2015; 11():229-43. PubMed ID: 25914541
[TBL] [Abstract][Full Text] [Related]
17. The highly potent and selective dipeptidyl peptidase IV inhibitors bearing a thienopyrimidine scaffold effectively treat type 2 diabetes.
Deng J; Peng L; Zhang G; Lan X; Li C; Chen F; Zhou Y; Lin Z; Chen L; Dai R; Xu H; Yang L; Zhang X; Hu W
Eur J Med Chem; 2011 Jan; 46(1):71-6. PubMed ID: 21106276
[TBL] [Abstract][Full Text] [Related]
18. Alogliptin benzoate for the treatment of type 2 diabetes.
Rendell M; Drincic A; Andukuri R
Expert Opin Pharmacother; 2012 Mar; 13(4):553-63. PubMed ID: 22296609
[TBL] [Abstract][Full Text] [Related]
19. Comparative Binding Analysis of Dipeptidyl Peptidase IV (DPP-4) with Antidiabetic Drugs - An Ab Initio Fragment Molecular Orbital Study.
Arulmozhiraja S; Matsuo N; Ishitsubo E; Okazaki S; Shimano H; Tokiwa H
PLoS One; 2016; 11(11):e0166275. PubMed ID: 27832184
[TBL] [Abstract][Full Text] [Related]
20. Alogliptin; a review of a new dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of type 2 diabetes mellitus.
Said S; Nwosu AC; Mukherjee D; Hernandez GT
Cardiovasc Hematol Disord Drug Targets; 2014; 14(1):64-70. PubMed ID: 24993124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]